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ABSTRACT: The microsolvated state of a molecule,
represented by its interactions with only a small number of
solvent molecules, can play a key role in determining the
observable bulk properties of the molecule. This is especially
true in cases where strong local hydrogen bonding exists
between the molecule and the solvent. One method that can
probe the microsolvated states of charged molecules is
differential mobility spectrometry (DMS), which rapidly
interrogates an ion’s transitions between a solvated and
desolvated state in the gas phase (i.e., few solvent molecules
present). However, can the results of DMS analyses of a class
of molecules reveal information about the bulk physicochem-
ical properties of those species? Our findings presented here
show that DMS behaviors correlate strongly with the measured solution phase pKa and pKb values, and cell permeabilities of a set
of structurally related drug molecules, even yielding high-resolution discrimination between isomeric forms of these drugs. This is
due to DMS’s ability to separate species based upon only subtle (yet predictable) changes in structure: the same subtle changes
that can influence isomers’ different bulk properties. Using 2-methylquinolin-8-ol as the core structure, we demonstrate how
DMS shows promise for rapidly and sensitively probing the physicochemical properties of molecules, with particular attention
paid to drug candidates at the early stage of drug development. This study serves as a foundation upon which future drug
molecules of different structural classes could be examined.
■ INTRODUCTION
Many studies involving microsolvated speciesisolated ions or
molecules bound noncovalently to a small, defined number of
solvent moleculesusually reflect on whether the knowledge
gained provides valuable insights into their analogous bulk-
solvated states.1 That is, do the properties of microsolvated
species teach us anything about the same molecules’ behavior as
observed in liquid solution? Ultimately, it is the presence of any
strong correlations observed between the properties of
microsolvated molecules and their bulk-solvated forms and a
reasonably argued theory explaining these relationships that
lend the best support to such comparisons.
Among the many analytical tools employed to study the
microsolvated states of molecules is differential mobility
spectrometry (DMS).2−4 While DMS is a technology known
more for its ability to separate analytical ions from chemical
noise,5 we have recently employed DMS to examine how the
microsolvation properties of ions are affected by their specific
structural attributes. For example, we have observed the
influence of electronic/resonance effects,6 the steric hindrance
of charge sites,7−9 and the influence of intramolecular hydrogen
bonding on DMS behavior.10 Based upon these recent
discoveries, we focused efforts on determining whether any
links could be made between the DMS-probed microsolvation
of molecules and their bulk physicochemical properties.
Medicinal chemistry, more specifically drug design, might
benefit from a technology such as DMS that could help predict
molecular physicochemical properties with sensitivity and
speed. Presently, during the early stages of small molecule
drug discovery, medicinal chemists try to relate a drug
candidate’s chemical structure and physicochemical properties
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to its cellular availability.11,12 Many of these properties can be
experimentally measured using cell-based permeability assays
(e.g., MDCK, RRCK, Caco-2),13 and physicochemical exami-
nation (e.g., pKa, shake-flask log D, PAMPA, turbidometry).
14
These benchtop in vitro studies serve as preliminary appraisals
of a molecule’s fitness to navigate biological barriers in vivo.
Unfortunately, existing methodologies lack the resolution to
discriminate between closely related structural analogues or
motifs.15,16 Moreover, while progress has been made in
streamlining these assays,17−19 they still require considerable
resources and experience suboptimal reproducibility.20,21
With this as our focus, we report on the use of DMS as a
probe of the microsolvated forms of drug molecules, and relate
the measured DMS behavior to those drug molecules’
condensed phase physicochemical properties. Here, we
demonstrate that the DMS properties of drug molecules,
which measure the molecule’s binding interactions with a protic
solvent vapor, correlate strongly with experimentally deter-
mined pKa, pKb, and cell permeability measurements. More-
over, these measurements require only a fraction of the time,
sample, and resources of current state-of-the-art techniques
(vide inf ra). These correlations derive from the ability of the
DMS instrument to probe the ion−solvent interactions of gas-
phase forms of drug molecules, which relates to both a drug
molecule’s inherent acidity/basicity (pKa/pKb) and its ability to
desolvate such that it might transit a hydrophobic lipid bilayer
(cell permeability). Our findings demonstrate that, in addition
to being able to distinguish isomeric drug molecules easily, the
DMS behaviors of drug molecules can be predicted based upon
subtle changes in structure related back to specific Hammett
parameters (σ+) and van der Waals radii of the functional
groups.
■ RESULTS AND DISCUSSION
The DMS Behaviors of Drug Molecules Correlate
Strongly with Their Passive Cell Permeabilities. In this
study, we employed DMS−MS to examine drug molecules that
shared a common core: 2-methylquinolin-8-ol (Scheme 1).
This drug and its analogues have been employed for years in a
variety of pharmaceutical applications and physicochemical
studies.22−32 In total, we examined 22 drug molecules: 7 triplets
of isomers (each bearing one of 7 functional groups in either
the 5-, 6-, or 7-position of the quinoline ring) as well as 2-
methylquinolin-8-ol itself. One of the reasons for choosing this
model drug chemistry was that several types of structural motifs
are present that could impact the microsolvation, as well as the
bulk physicochemical properties of these molecules; the
different functional groups provide opportunities for varied
steric and electronic effects to be present, as well as the
presence of intramolecular hydrogen bonds (IMHBs), that
could also impact the behavior of these molecules. Overall, our
aim was to relate the DMS-based ion−solvent interaction
measurements to in vitro diagnostics of interest to medicinal
chemists, including the passive cell permeability using the
Ralph-Russ Canine Kidney (RRCK) method33 and exper-
imentally determined pKa/pKb measurements.
19,34 These
conventional methodologies are described in more detail in
the Supporting Information.
The critical DMS output that relates directly to a specific
molecule’s solvent binding energy is the relationship between
the applied separation voltage (SV) and the measured optimum
compensation voltage (CV) for transmission of the ionized
drugs through the DMS cell (see Supporting Information for
further detail).9 For example, Figure 1 depicts the results of the
DMS CV-ramping experiments conducted with three isomers
of methoxy-2-methylquinolin-8-ol and fluoro-2-methylquinolin-
8-ol where SV was stepped from 0 to 4000 V. There are clear
trends for each drug as the site of substitution is varied from the
5-, to 6-, to 7-positions (see Scheme 1).
The more negative the CV shift experienced by the
protonated drug molecule, the stronger the interaction with
the solvent vapor that molecule exhibits.7,9 Thus, for both the
methoxy- and fluoro-substituted drugs, the 7-substituted isomer
displayed the weakest ion−solvent interaction, followed by the
5- and then the 6-substituted isomers. Moreover, the overall
magnitude of the negative CV shifts was greater for the fluoro-
substituted drugs than for the methoxy-substituted species,
revealing the greater ion−solvent interactions of the fluoro-
substituted molecules (vide inf ra). Similar DMS-based exami-
nations were conducted for all 22 drug molecules. Ultimately,
we have found that the SV value at which at ion’s CV reaches a
minimum value (SV@CVmin) represents a measure for the ion’s
desolvated/solvated equilibrium,2,3,7,35 and overall, its ion−
solvent binding (i.e., microsolvation) energy.9
Our comparison of the DMS data with the experimental
physicochemical data yielded strong and promising correla-
tions. Figure 2 plots cell permeability values and SV@CVmin
measurements for three sets of structural isomers: methoxy-,
chloro-, and cyano-2-methylquinolin-8-ol derivatives. It is clear
that SV@CVmin measurements track with the relative cell
Scheme 1. Structures of the 2-Methylquinolin-8-ol Molecules
Analyzed in This Study (22 in Total)
Figure 1. DMS dispersion plots (A) methoxy-2-methylquinolin-8-ol
and (B) fluoro-2-methylquinolin-8-ol in a N2 environment seeded with
1.5% methanol vapor. Substitution occurs at the 5- (black squares), 6-
(red circles), and 7-positions (blue triangles).
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permeability for each isomer of a given substituent. The subtle
structural differences between these drug isomers can affect
their respective solvent binding energies, resulting in the drugs’
distinct relative cell permeabilities. For example, the more
strongly microsolvated 6-substituted 2-quinolin-8-ol derivatives
(i.e., those with larger SV@CVmin values) display lower cellular
permeability than the 5- and 7-substituted species. This result
supports our hypothesis that stronger ion−solvent interactions
correlate with slower desolvation and transport kinetics at the
cell membrane, thereby lowering the rate of passive diffusion.
Similar comparisons for all seven substituent groups are
presented in Figure S1. The relationship between the observed
DMS ion−solvent interaction and relative passive cell
permeability is in accord with the general thinking behind the
mechanism of passive transport of drug molecules across cell
membranes.36−39 As a drug molecule exhibits a greater
tendency to shed solvent molecules from its immediate
environment, it can then begin to interact with a cell’s outer
wall and proceed to transit this barrier.
In general, cell permeability is significantly higher for all 7-
substituted isomers compared with their 5- and 6-substituted
analogues. While this trend was consistent across the 2-
methylquinolin-8-ol isomers for a particular substituent (Figure
2), the ion−solvent interactions of the different substituted
derivatives (e.g., methoxy versus cyano) were not directly
correlated with apparent cell permeability. For example, 7-
methoxy-2-methylquinolin-8-ol and 7-cyano-2-methylquinolin-
8-ol both exhibited a cell permeability of ∼3 × 10−6 cm s−1, but
the SV@CVmin value for the 7-cyano derivative was significantly
larger than that for the 7-methoxy analogue. Based on our
hypothesis, we would expect greater cell permeability for the 7-
methoxy analogue than for the 7-cyano species due to the
weaker microsolvation of the methoxy species (i.e., lower values
of SV@CVmin). These differences are presently under
investigation.
The DMS Behaviors of Drug Molecules Also Correlate
Strongly to pKa and pKb Measurements. The exper-
imentally measured pKa and pKb values for the 2-
methylquinolin-8-ol derivatives also correlate strongly with
the DMS results. We observe that species with lower pKa and
pKb values exhibit greater ion−solvent interactions (see Figures
3A and 3B); the 5- and 6-substituted 2-methylquinolin-8-ol
derivatives show strong correlations, but the 7-substituted
isomers exhibit greater variability in this relationship (Figure 3,
blue squares). We attribute this variability in the pKa/pKb−
DMS correlation plots for the 7-substituted species to the
variability in chemical and physical interactions between 7-
position substituents and solvent molecules (afforded by the
closer proximity to the solvent binding site). Indeed, we find
that the data points which are furthest from the pKa/pKb−DMS
correlation trend line are all associated with 7-substituted
species that exhibit NH−solvent binding, rather than the more
common OH solvent binding motif (hollow blue squares in
Figure 3). In other words, the variability in the physicochemical
properties of the 7-substituted derivatives arises due to steric
effects, which in turn influence the solvent binding motif. The
strong correlations that we observe for the 5- and 6-substituted
species, on the other hand, demonstrate that DMS ion−solvent
clustering measurements are sensitive to steric and electronic
effects (vide inf ra).
Rationalizing the Correlations between DMS Behav-
iors and Physicochemical Properties. The ability for the
DMS to measure SV@CVmin values for a large collection of
Figure 2. Plots showing the correlation between RRCK-based cell
permeabilities (blue bar graphs) and SV@CVmin (yellow data points)
as a function of substitution position for the (top) methoxy-, (middle)
chloro-, and (bottom) cyano-substituted 2-methylquinolin-8-ol
derivatives.
Figure 3. Experimentally determined (A) pKa (R
2 = 0.70), and (B)
pKb (R
2 = 0.62), as a function of SV@CVmin for 2-methylquinolin-8-ol
derivatives: (black) 5-substituted, (red) 6-substituted, and (blue) 7-
substituted species. Filled squares are species that bind to solvent via
the OH group, while hollow blue squares are species that exhibit NH−
solvent binding.
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drug molecules both rapidly (∼2 min per analysis) and with
great sensitivity (only picograms of material are required)
makes the observed correlations between the DMS data and the
physicochemical parameters very compelling. But what is the
nature of the underlying mechanisms that link these gas-phase
measurements with the mated in vitro experiments?
First, we must examine the other parameters with which
DMS displays strong correlations: calculated ion−solvent
binding energies (i.e., microsolvation energies) and functional
group-specific linear free energy parameters (e.g., σ+ values).
The correlation between the DMS results and the calculated
solvent binding energies for the twenty two 2-methylquinolin-
8-ol species support a hypothesis that steric and electronic
effects account for the observed variations in CVs. In addition,
the fact that the binding energy for a single solvent molecule
correlates best with the DMS data also supports a mechanism
wherein a strong local hydrogen bond is playing a key role.40
Figures 4A and 4B plot the calculated methanol binding
energies against measured DMS SV@CVmin for the 5- and 6-
substituted 2-methylquinolin-8-ol species, respectively. Clearly,
species which bind solvent molecules more strongly exhibit
greater SV@CVmin values as measured by DMS. Figure 4C
displays the correlation between binding energy and measured
CV for the 7-substituted species. In this case, the voltages
required to correct the ion trajectories encompass a much
broader range and the correlation with calculated binding
energies is poorer. As was the case with the pKa/pKb
correlations (vide supra), the relatively poor correlation
between calculated solvent binding energy and DMS ion
trajectory for the 7-substituted species arises due to steric
effects, which ultimately influence whether the solvent molecule
is bound to the OH group or to the NH group. The data points
for the 7-substituted species that favor the NH−solvent binding
motif are plotted as hollow squares in Figure 4C. In general, the
NH-bound solvent clusters exhibit weaker calculated binding
energies and DMS-measured microsolvation energies than the
species which favor the OH−solvent binding motif. Given the
fact that across the series of 7-substituted derivatives we are
probing two different ion−solvent binding motifs, each of
which will exhibit inherently different clustering/declustering
dynamics, it is not unreasonable to expect a higher degree of
variability in the correlation plot.
Also plotted in Figure 4 are the substituent-specific DMS
behaviors of the electron-donating (ED) and electron-with-
drawing (EW) groups, which are apparent for the 5-subsituted
species through strong correlations with Brown and Okamoto’s
σP
+ constants (i.e., Hammett parameters; Table S1).41,42
Similarly, the DMS behavior of the 6-substituted species trends
consistently with the meta-position electrophilic substituent
constants (σM
+, Table S1). However, as was the case with
calculated solvent binding energies, the 7-substituted species
exhibit a comparatively weaker correlation when plotting σp
+
versus measured SV@CVmin. Again, we attribute this to the
convolution of resonance and steric effects for substituents at
the 7-position,23,24 a conclusion that we base on the fact that
the species which exhibit NH−solvent binding (Figure 4C,
hollow blue squares) seem to follow a slightly different trend
than those which exhibit OH−solvent binding (Figure 4C,
filled blue squares). Note also that substituents in the 7-
position can potentially influence the microsolvation process
via formation of an intramolecular hydrogen bond (IMHB)
with the proton of the 8-hydroxy group (e.g., 7-nitro; see
Supporting Information).43 This notion is supported by the fact
that, when the data for the 7-nitro substituted drugs are
removed from the linear regression model of the DMS data
comparison with cell permeability, pKa, or pKb (Figure S2,
Table S3), the correlation improves. Further support for this
conclusion comes from the calculated lowest-energy cluster
geometries; many of the 7-substituted 2-methylquinolin-8-ol
derivatives exhibit structures that suggest the possibility of
intramolecular hydrogen bonding (see Supporting Informa-
tion).9 Moreover, our findings here are supported by past
studies where the effects of electron-donating and electron-
withdrawing substituents (and their respective σ or σ+
constants) on pKa
23,24,26,29 and solubility30,32 have been
examined for quinoline-8-ol derivatives. Ultimately, this
apparent influence of electronic effects on DMS separation
suggests a connection to linear free energy relationship and
possibly to quantitative structure−activity relationships
(QSAR).44,45
The behavior of the 7-substituted 2-methylquinolin-8-ol
derivatives is similar to that of the 5-substituted isomers by
virtue of the analogous electronic effects (i.e., charge
delocalization) present (Scheme 2). However, the 7-substituted
species induce a weaker ion−solvent binding interaction due to
steric hindrance arising from the proximity of the functional
group to the site of solvent binding. For all 5- and 6-substituted
derivatives, solvent molecules were calculated to bind to the 8-
hydroxy group in the lowest energy structures (see Supporting
Information). However, as mentioned above, in some cases the
global minima for the 7-substituted ion−solvent clusters
exhibited NH-bound solvent molecules. Interestingly, this
Figure 4. Plots displaying the correlations between the observed SV@
CVmin measurements, calculated methanol binding energies, and sigma
parameters (σP
+ for 5- and 7-substitution; σM
+ for 6-substitution) for
the (A) 5-substituted (R2BE = 0.67; R
2
s = 0.91), (B) 6-substituted (R
2
BE
= 0.97; R2σ = 0.99), and (C) 7-substituted (R
2
BE = 0.86; R
2
σ = 0.54) 2-
methylquinolin-8-ol derivatives.
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apparent trend in microsolvation of 7-substituted species tracks
well with the van der Waals radii of the substituents (Table S3,
Figures S7−S9). Derivatives in which the substituent in the 7-
position was smaller than the methyl group in the 2-position
exhibited OH−solvent binding (as was observed for the 5- and
6-substituted species). However, when the substituent in the 7-
position was larger than the methyl group in the 2-position,
NH−solvent binding was favored. These steric effects are
visualized in Figures S7 and S8, which plot substituent van der
Waals radii as a function of the relative isomer energies (i.e.,
OH-bound versus NH-bound). Given this clear steric effect, we
postulate that 7-substituted derivatives are more easily
desolvated owing to the fact that substituents in the 7-position
can disrupt the extended hydrogen bonding network near the
site of solvent nucleation. Further to this, nitro and methoxy
groups in the 7-position are also capable of changing the
microsolvation environment by forming intramolecular hydro-
gen bonds with the 8-hydroxy group. Thus, these species
contain an intramolecular “switch”, which (when engaged)
enhances molecular lipophilicity.46 Taken as a whole, these
interactions weaken the ion−solvent binding energy of 7-
substituted species, and this is reflected in their lower SV@
CVmin values and enhanced cell permeabilities.
These relationships (as well as other previously identified
DMS parameters,7 Figure S2) reveal the impact of molecular
structure on the DMS results (Figures 2, 3). Based upon the
relative CV shifts observed, we conclude that the positioning of
the substituents on the quinoline moiety affected micro-
solvation by providing (1) different degrees of electron
donation/withdrawal from the quinoline system and (2)
different levels of steric hindrance for the formation of stable
ionized solute/solvent clusters. We have previously demon-
strated the influence of steric hindrance in DMS, specifically in
a set of quinoline molecules structurally similar to those studied
here.9 Based upon those results, we initially hypothesized that
the closer the substituent on the quinoline ring to the site of
charging, the weaker the microsolvation energy should be (i.e.,
ion−solvent binding energy for 5- < 6- < 7-substituted species).
However, if the substituents are able to donate electron density
to, or withdraw electron density from, the quinoline ring
conjugated π-system, they would influence the molecular
charge densities via resonance. As a result, ion−solvent
interactions should be determined by substituent inductive
resonance effects, which in turn influence ion−solvent
electrostatic interactions (e.g., charge-dipole, hydrogen-bond-
ing). For example, species with electron-withdrawing groups
(e.g., −CN) should display stronger microsolvation energies
because the positive partial charges at the ring NH and OH
groups, the sites of solvent nucleation, will be enhanced.
From the DMS data (Figure S3, Table S1), we observe that
the microsolvation energies of these species are not determined
solely by the geometric distance of the substituent from the site
of solvent binding (i.e., the protonated ring nitrogen and 8-
hydroxyl group);9 the electron-donating/withdrawing charac-
teristics of the substituents in the 5-, 6-, and 7-positions are also
found to play a major role in ionized solute−solvent
interactions. Upon protonation of the ring nitrogen atom,
resonant charge delocalization results in relatively high partial
charges at the 1-, 2-, 4-, 5-, 7-, and 10-positions of the quinoline
moiety. This increased positive charge of the ring system
enhances the polarization of the hydroxyl group in the 8-
position. When we consider the putative resonance structures
of the 2-methylquinolin-8-ol derivatives (Scheme 2) and their
possible roles in the observed DMS behavior, we note that
substituents in the 6-position do not influence charge density of
the ring system at the aforementioned positions via resonance.
In this case, charge is delocalized through the π-system to a
lesser extent and solvent clustering is generally strongest due to
the more localized, stable charge site, compared with
substitutions at 5- and 7-positions. While all 6-position
substituents cluster strongly, the electron-donating substituents
(e.g., methyl and methoxy) form weaker solvent clusters
compared with electron-withdrawing congeners. For example,
the SV@CVmin value and calculated ion−solvent binding
energy for protonated 6-methoxy-2-methylquinolin-8-ol reveal
a more weakly microsolvated species than the 6-cyano analogue
(see Table S1), as expected based on electron-donating/
withdrawing arguments. These differences in microsolvation
energy as a function of substituent correlate strongly with the
electron-donating/withdrawing properties of the functional
groups (see Table S1).
We also find that the 7-substituted isomers exhibit weaker
clustering interactions than do the 5-substituted isomers. Note
that 7-position methoxy, methyl, and bromo substituents have
>10-, 3-, and 4-fold weaker solvent binding, respectively,
compared with their 5-position isomers. This difference in ion−
solvent interaction strength likely arises from a moderate steric
effect due to the location of the 7-substituted group proximal to
the protonated ring nitrogen and 8-hydroxy group (viz., the site
of solvent binding).7,9 These structural changes may serve to
destabilize the solvent shell that forms during the low-field
portion of the DMS cycle. Ultimately, the 7-substituted
molecules exhibit weaker microsolvation energies that may be
reflective of their ability to easily desolvate/solvate as biological
barriers are traversed (vide inf ra).
Addressing the Possible Importance of the Strong
Local Hydrogen Bond in DMS and Physicochemical
Experiments. To study drug candidates using mass spectrom-
etry, it is necessary to probe the ionized forms (e.g., protonated
2-methylquinolin-8-ol derivatives). Nevertheless, while we are
examining the solvent binding properties of the protonated
species, we can extend the results obtained here to the neutral
drug molecule counterparts. It is also important to note that the
protonated forms of many drugs (such as these quinoline-8-ol
derivatives) may play a key role in absorption given the pH of
the gut environment in vivo (from pH ∼1.7 in the stomach to
∼6.5 in the intestines).47 For the quinoline-8-ol derivatives
studied here, the ring nitrogen, which is the locus of greatest
Scheme 2. Resonance Structures for the 5-, 6-, and 7-
Substituted 2-Methylquinolin-8-ol Derivatives
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electron density, is also the site of protonation (e.g., see Figure
5).9,48,49 This and the adjacent OH group of the quinolin-8-ol
derivatives are the principal sites of interaction for solvent
molecules in both the protonated and neutral molecules. Thus,
the protonated analogue is a useful example of the hydrogen
bonding experienced by these drug molecules in bulk aqueous
(protic) solution; intermolecular hydrogen bonding is the first
step in protonation of a molecule, and these motifs have been
characterized as resembling the initial stages of the proton-
transfer process.40,50,51
We also find that the binding energy of the first solvent
molecule exhibits the strongest correlation to the DMS data.9
This accords with the hypothesis that we are probing the initial
instances of the prompt solvation mechanism52 that includes a
strong local hydrogen bond formed between the drug molecule
and the first solvating molecule.53 When considering the
computational accuracy of pKa prediction, Kelly and co-workers
recognized that their calculations only tracked with exper-
imental observations when a single explicit solvent molecule
was included.53,54 While the DMS studies described herein
differ from the more traditional “ion solvation” type studies
conducted with mass spectrometry (i.e., where specific numbers
of solvent molecules bound to an ion have been detected
explicitly), some of these studies have revealed the importance
of the initial ion−solvent molecule interaction.55−57
The work that we present here evaluates the microsolvation
properties of 2-methylquinolin-8-ol derivatives with water and
methanol. In future work we will investigate the effects of other
volatile solvents in the DMS environment to assess the specific
roles of other polar and nonpolar solvents.58 Lastly, given the
demonstrated ability of DMS to separate isomeric drug species
based upon simple substitution patterns of EW and ED groups,
one could envision using DMS−MS as a high-throughput
platform (e.g., requiring a few minutes, not hours or days)59 for
assessing Hammett parameters experimentally, with very high
degrees of both sensitivity and selectivity. While relationships
between specific σ+ constants and solvation energies have
previously been postulated,60,61 to our knowledge, this is the
first time the correlation has been demonstrated experimentally.
■ CONCLUSIONS
In this study, we demonstrate that DMS can be used to assess
the physicochemical properties of drug molecules by probing
the behavior of their microsolvated forms in a robust and
precise manner. These results are supported by a number of
orthogonal methods, including empirically parametrized
Hammett parameters and extensive computational modeling.
The parallel study of DMS-determined solvent binding
properties and calculated geometric and electronic structure
allows us to relate the structural properties of a drug to its
experimentally determined pKa and pKb values, and its relative
cell permeability.
Overall, the correlation of DMS measurements and cell
permeabilities of isomeric drugs can complement the cell-based
measurements by presenting additional ways for medicinal
chemists to rationalize the impact of steric and electronic effects
within a chemical series. Furthermore, the SV@CVmin end
points are very precise (<2%) and consistent across day-to-day
replicate experiments, a far greater reproducibility than cell-
based assays can typically achieve.10 Hence, the combination of
cell- and DMS-based methodologies could yield finer
distinction between structural motifs to guide drug design.
Consequently, DMS is a very promising new tool for rational
drug design, where identifying and describing subtle steric and
electronic interactions for a given drug structural motif
facilitates the testing of structure−activity relationship hypoth-
eses.
■ MATERIALS AND METHODS
Materials. Substituted 2-methylquinolin-8-ol derivatives
(Scheme 1) were purchased from ACES Pharma (Princeton,
NJ) and were used without further purification. HPLC grade
acetonitrile and methanol were bought from Caledon
Laboratory Chemicals (Georgetown, ON, Canada), and formic
acid was purchased from Sigma-Aldrich (Oakville, ON,
Canada). Distilled deionized water (18 MΩ) was produced
in-house using a Millipore (Billerica, MA, USA) Integral 10
water purification system.
DMS−MS System. A DMS system (SCIEX, Concord, ON)
was mounted on a hybrid quadrupole linear ion trap mass
spectrometer (SCIEX) system in the atmospheric region
between the sampling orifice and its electrospray ionization
(ESI) source.5,35 The ESI probe was maintained at a voltage of
5500 V. A constant gas flow in the DMS cell was achieved by
the curtain gas flow (N2; 30 psi, 7.1 L/min) and the primary
stage vacuum pumping of the MS system. The temperature of
the transport gas in the DMS cell was maintained at ∼100 °C
(DMS heater setting of 150 °C). Methanol or water could be
added to the curtain gas at 1.5% by a PerkinElmer 200 LC
pump (Waltham, MA). In each experiment, analytes were
dissolved in solution (50/50 acetonitrile/water with 0.1%
formic acid) to a concentration of 100 ng/mL. Each solution
was infused into the ESI source (5500 V spray voltage) at a rate
of 7 μL/min.
The fundamental behavior of the DMS has been described
elsewhere.2−4,62 These experiments begin by subjecting a
solution of drug molecules to ESI, producing gas-phase ions
for these species. These ions are then sampled by the DMS cell:
two parallel plates across which an asymmetric rf waveform
(the separation voltage or SV) is applied (Figure S5). The ion’s
transit through the DMS cell will depend upon the amplitude
of the SV (generally held at a constant value) and an additional
Figure 5. Charge density plots for both the neutral (top row) and
protonated (bottom row) forms of three different isomers of fluoro-2-
methylquinolin-8-ol. Red regions correspond to greater electron
density (partial negative charge), while blue coloring maps to lesser
electron density (partial positive charge).
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dc voltage (compensation voltage or CV) used to stabilize the
ion’s trajectory. When we purposefully add solvent vapor (e.g.,
water, methanol) to the DMS cell, the ions undergo dynamic
clustering/declustering cycles as their trajectory and kinetic
energies oscillate with the rf waveform (see Supporting
Information for more detail). Consequently, the probed species
undergo incipient solvation several thousand times as they
transit the DMS cell. Since the collision and clustering
properties of an ion also relate directly to the structural
features of the ion itself, the SV/CV settings required for
optimal transmission encode the statistically sampled geo-
metries and interaction potentials of the ions with the solvent
vapor molecules.35
Computational Methods. To identify the most stable
ion−solvent cluster structures, cluster potential energy land-
scapes were mapped with a custom written basin-hopping
(BH) algorithm.63 Details of our implementation of the BH
algorithm are reported elsewhere where we have demonstrated
this methodology as an accurate means of assessing ion−
solvent binding.7,9,64,65 Convergence criteria were set to the
default criteria of the Gaussian 09 suite of programs.66 Cluster
systems were modeled using the AMBER force field, with
atomic partial charges calculated for the monomers with the
CHelpG partition scheme67 at the B3LYP/6-31+G(d,p) level
of theory.68,69 For each BH step, a random rotation of −20° ≤
θ ≤ 20° was applied about the body-fixed x, y, and z axes for
each solvent molecule, and each solvent molecule was also
randomly translated by −0.7 Å ≤ η ≤ 0.7 Å in the x, y, and z
directions. BH searches explored ∼20,000 structures for
clusters containing one solvent molecule. Unique isomers
identified by the BH routine were optimized at the B3LYP/6-
311++G(d,p) level of theory68,69 employing the GD3 empirical
dispersion correction.70 Normal mode analyses were conducted
for each isomer to ensure that it corresponded to a local
minimum on the potential energy surface. In all cases, we
determined that protonation occurred on the ring nitrogen. All
cluster structures and XYZ coordinates are available in the
Supporting Information. To account for basis-set superposition
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